Igκ gene segment usages, nucleotides insertions, and CDR3 sequences in IgM+κ+CD21lowCD27+ B cells
| Subject no./status . | Vκ . | Jκ . | VJ (P,N) . | Igκ CDR3 sequence . |
|---|---|---|---|---|
| LDU 077/HCV Ab− | ||||
| Clones, no. | ||||
| 1/8 | 4-1*01 | 2*01 | 0,20 | CHQYYAFPHTFGO |
| 1/8 | 2-28*01 | 4*01 | 1,2 | CMQALQTPLTFGG |
| 1/8 | 1-39*01 | 2*01 | 1,10 | CQQSYSTPSHTFGQ |
| 1/8 | 1-33*01 | 2*01 | 0,0 | CQQYDNLPPYTFGQ |
| 1/8 | 3-20*01 | 1*01 | 0,15 | CQHYRSSLWTFGQ |
| 1/8 | 2-29*01 | 1*01 | 1,17 | CMQGLHLPPTFGQ |
| 1/8 | 1-8*01 | 1*01 | 2,0 | CQQYYSYPRTFGQ |
| LDU 095/HCV Ab− | ||||
| Clones, no. | ||||
| 1/2 | 4-1*01 | 4*01 | 0,0 | HQYYRTPLTFGG |
| 1/2 | 1-39*01 | 2*01 | 0,0 | CQQSYRTPHTFGQ |
| 773/HCV+MC+ | ||||
| Clones, no. | ||||
| 7/12* | 3-20*01 | 1*01 | 0,1 | CQQYGSSPQTFGQ |
| 4/12* | 3-20*01 | 1*01 | 0,1 | CQQYGSSPQTFGQ |
| 1/12 | 3-20*01 | 1*01 | 1,1 | CQQYGSSRTFGQ |
| 1403/HCV+MC+ | ||||
| Clones, no. | ||||
| 9/18* | 3-20*01 | 4*01 | 0,0 | CQQYGSSPTFGG |
| 5/18* | 3-20*01 | 2*01 | 1,0 | CQQYGSSRYTFGQ |
| 1/18 | 3-20*01 | 2*01 | 1,0 | CQQYGSSPYTFGQ |
| 1/18 | 3-20*01 | 4*01 | 2,0 | CQQYGSSSLTFGG |
| 1/18 | 1-27*01 | 4*01 | 0,0 | CQKYNSAPLTFGG |
| 1/18 | 1-6*01 | 2*01 | 0,0 | CLQDYNYPYTFGQ |
| 1308/HCV+MC+ | ||||
| Clones, no.: 15/15* | 3-15*01 | 1*01 | 0,0 | CQQYNNWPPWTFGQ |
| 1432/HCV+MC+ | ||||
| Clones, no.: 22/22* | 3-20*01 | 2*02 | 1,1 | CQQYGSSPRTFGQ |
| Subject no./status . | Vκ . | Jκ . | VJ (P,N) . | Igκ CDR3 sequence . |
|---|---|---|---|---|
| LDU 077/HCV Ab− | ||||
| Clones, no. | ||||
| 1/8 | 4-1*01 | 2*01 | 0,20 | CHQYYAFPHTFGO |
| 1/8 | 2-28*01 | 4*01 | 1,2 | CMQALQTPLTFGG |
| 1/8 | 1-39*01 | 2*01 | 1,10 | CQQSYSTPSHTFGQ |
| 1/8 | 1-33*01 | 2*01 | 0,0 | CQQYDNLPPYTFGQ |
| 1/8 | 3-20*01 | 1*01 | 0,15 | CQHYRSSLWTFGQ |
| 1/8 | 2-29*01 | 1*01 | 1,17 | CMQGLHLPPTFGQ |
| 1/8 | 1-8*01 | 1*01 | 2,0 | CQQYYSYPRTFGQ |
| LDU 095/HCV Ab− | ||||
| Clones, no. | ||||
| 1/2 | 4-1*01 | 4*01 | 0,0 | HQYYRTPLTFGG |
| 1/2 | 1-39*01 | 2*01 | 0,0 | CQQSYRTPHTFGQ |
| 773/HCV+MC+ | ||||
| Clones, no. | ||||
| 7/12* | 3-20*01 | 1*01 | 0,1 | CQQYGSSPQTFGQ |
| 4/12* | 3-20*01 | 1*01 | 0,1 | CQQYGSSPQTFGQ |
| 1/12 | 3-20*01 | 1*01 | 1,1 | CQQYGSSRTFGQ |
| 1403/HCV+MC+ | ||||
| Clones, no. | ||||
| 9/18* | 3-20*01 | 4*01 | 0,0 | CQQYGSSPTFGG |
| 5/18* | 3-20*01 | 2*01 | 1,0 | CQQYGSSRYTFGQ |
| 1/18 | 3-20*01 | 2*01 | 1,0 | CQQYGSSPYTFGQ |
| 1/18 | 3-20*01 | 4*01 | 2,0 | CQQYGSSSLTFGG |
| 1/18 | 1-27*01 | 4*01 | 0,0 | CQKYNSAPLTFGG |
| 1/18 | 1-6*01 | 2*01 | 0,0 | CLQDYNYPYTFGQ |
| 1308/HCV+MC+ | ||||
| Clones, no.: 15/15* | 3-15*01 | 1*01 | 0,0 | CQQYNNWPPWTFGQ |
| 1432/HCV+MC+ | ||||
| Clones, no.: 22/22* | 3-20*01 | 2*02 | 1,1 | CQQYGSSPRTFGQ |
VJ (P,N) indicates the number of palindromic (P) and nontemplated (N) nucleotides inserted at the VJ join. The bold type in the Igκ CDR3 sequence indicates aa residues between position 106 and the conserved phenylalanine in all Jκ segments.
in column 1 indicates clonal populations.